Hu-Lieskovan et al.34 indicated that B-RAF inhibitors combined with MEK inhibitors and anti-PD-L1 led to further reduction of tumor growth in vivo in a syngeneic mouse model of melanoma. This evidence concerns the gene MAP2K7 and neoplasm.